These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 20265267)

  • 21. Post-kala-azar dermal leishmaniasis and visceral leishmaniasis in a child--or is it para-kala-azar dermal leishmaniasis?
    Mendiratta V; Chander R
    Int J Dermatol; 2009 Sep; 48(9):1027-8. PubMed ID: 19703001
    [No Abstract]   [Full Text] [Related]  

  • 22. [Histopathology of Chagas' disease and of kala-azar in naturally infected dogs].
    de ALVARENGA R
    Hospital (Rio J); 1960 Jan; 57():23-40. PubMed ID: 13793011
    [No Abstract]   [Full Text] [Related]  

  • 23. Histopathological characteristics of post kala-azar dermal leishmaniasis: a series of 88 patients.
    Singh A; Ramesh V; Ramam M
    Indian J Dermatol Venereol Leprol; 2015; 81(1):29-34. PubMed ID: 25566893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidemiology of visceral leishmaniasis in India.
    Bora D
    Natl Med J India; 1999; 12(2):62-8. PubMed ID: 10416321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Histopathological skin changes after kala-azar: post-kala azar dermal leishmaniasis].
    MAJUMDAR TD
    Arch Klin Exp Dermatol; 1956; 203(5):483-502. PubMed ID: 13382178
    [No Abstract]   [Full Text] [Related]  

  • 26. Immunochromatographic (rK39) strip test in the diagnosis of visceral leishmaniasis in Bangladesh.
    Sarker CB; Momen A; Jamal MF; Siddiqui NI; Siddiqui FM; Chowdhury KS; Rahman S; Talukder SI
    Mymensingh Med J; 2003 Jul; 12(2):93-7. PubMed ID: 12894040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
    Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
    J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The epidemiology of visceral leishmaniasis and asymptomatic leishmanial infection in a highly endemic Bangladeshi village.
    Bern C; Haque R; Chowdhury R; Ali M; Kurkjian KM; Vaz L; Amann J; Wahed MA; Wagatsuma Y; Breiman RF; Williamson J; Secor WE; Maguire JH
    Am J Trop Med Hyg; 2007 May; 76(5):909-14. PubMed ID: 17488915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
    Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
    Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infectivity of Post-Kala-azar Dermal Leishmaniasis Patients to Sand Flies: Revisiting a Proof of Concept in the Context of the Kala-azar Elimination Program in the Indian Subcontinent.
    Molina R; Ghosh D; Carrillo E; Monnerat S; Bern C; Mondal D; Alvar J
    Clin Infect Dis; 2017 Jul; 65(1):150-153. PubMed ID: 28520851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Epidemiological characteristics of Kala-azar disease in China, during 2005-2015].
    Zheng CJ; Xue CZ; Wu WP; Zhou XN
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Apr; 38(4):431-434. PubMed ID: 28468057
    [No Abstract]   [Full Text] [Related]  

  • 32. Application of electroimmunodiffusion and crossed electroimmunodiffusion tests for the diagnosis of visceral leishmaniasis (kala-azar).
    Kohanteb J; Rezai HR; Ardehali S
    J Trop Med Hyg; 1984 Oct; 87(5):201-5. PubMed ID: 6442365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post kala azar dermal leishmaniasis in Sudan.
    Kordofani YM; Nour YT; El-Hassan AM; Shalayel MH
    East Mediterr Health J; 2001 Nov; 7(6):1061-4. PubMed ID: 15332749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Kala-azar in immunosuppressed patients. Apropos of a case disclosed by skin lesions].
    Frances C; Merle Beral H; Franceschini P; Lessana-Leibowitch M; Escande JP
    Presse Med; 1984 Nov; 13(40):2433-6. PubMed ID: 6239222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Performance of kala-azar surveillance in Gaffargaon subdistrict of Mymensingh, Bangladesh.
    Rahman KM; Samarawickrema IV; Harley D; Olsen A; Butler CD; Sumon SA; Biswas SK; Luby SP; Sleigh AC
    PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003531. PubMed ID: 25860258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Post-kala-azar dermal leishmaniasis (PKDL): the first case report from Nepal.
    Karki P; Koirala S; Parija SC; Sethi M; Das ML
    Southeast Asian J Trop Med Public Health; 2003 Mar; 34(1):22-3. PubMed ID: 12971510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blindness following visceral leishmaniasis: a neglected post-kala-azar complication.
    Khalil EA; Musa AM; Younis BM; Elfaki ME; Zijlstra EE; Elhassan AM
    Trop Doct; 2011 Jul; 41(3):139-40. PubMed ID: 21676981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Visceral leishmaniasis (kala-azar), Sudanese type.
    Buckner W
    Va Med Mon (1918); 1966 Aug; 93(8):455-8. PubMed ID: 5975075
    [No Abstract]   [Full Text] [Related]  

  • 39. [Schistosomiasis mansoni, Chagas disease, megaesophagus and kala-azar in Bahia].
    PRATA AR
    Arq Bras Med Nav; 1955 Dec; 16(56):4029-34. PubMed ID: 13283924
    [No Abstract]   [Full Text] [Related]  

  • 40. [Visceral leishmaniasis in Niger: six new parasitologically confirmed cases].
    Djidingar D; Chippaux JP; Gragnic G; Tchani O; Meynard D; Julvez J
    Bull Soc Pathol Exot; 1997; 90(1):27-9. PubMed ID: 9264745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.